ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) finished Wednesday with an addition of $0.21 to close at $17.84, an upside of 1.19 percent. An average of 745,020 shares of common stock have been traded in the last five days. There was a gain of $0.97 in the past week. The last 20 days have seen an average of 1,117,390 shares traded, while the 50-day average volume stands at 1,257,056.
ACAD stock has increased by 13.05% in the last month. The company shares reached their 1-month lowest point of $15.68 on 09/14/21. With the stock rallying to its 52-week high on 01/08/21, shares of the company touched a low of $15.68 and a high of $57.46 in 52 weeks. In spite of this, the price is down -68.95% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
167 days have passed since ACADIA Pharmaceuticals Inc. (ACAD) last reported insider trading activity. Ridloff Elena, who is EVP and CFO, most recently acquired $1,032 shares at $20.33 per share on Apr 30. In this transaction, the insider spent $20,981. EVP & General Counsel, KIM AUSTIN D., disposed of 1,054 shares at a price of $20.33 on Apr 30. The insider now owns more than $21,428 worth of shares. Prior to that, President Stankovic Srdjan R. went on to Sale 4,230 shares at $20.33 each on Apr 30. An amount of $85,996 was transacted.
ACADIA Pharmaceuticals Inc. (ACAD) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 0.59. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 6.23, the price-to-book (PB) ratio at 5.07.
The quick ratio of ACADIA Pharmaceuticals Inc. for the three months ended June 29 was 6.70, and the current ratio was 6.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. On the profitability front, the trailing 12-month gross margin is 95.70% against a 5-year average of 89.1%. ACADIA Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -52.26%, while its operating margin for the same period stands at -56.90%. Its gross profit as reported stood at $431.54 million compared to revenue of $441.75 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, ACADIA Pharmaceuticals Inc.’s return on assets was -34.20%, compared to -51.0% over the last five years. In the past year, the return on investment has been -45.80%, and the 5-year average is -57.6%. Meanwhile, the return on equity (ROE) for the past 12 months has been -43.10% and the 5-year average holds at -57.2%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, ACADIA Pharmaceuticals Inc. had $289.96 million in cash. The analyst consensus anticipated ACADIA Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.3 per share, but it turned out to be -$0.27, a 10.00% surprise. For the quarter, EBITDA amounted to -$42.29 million. Shareholders own equity worth $160.64 million.
From a technical analysis perspective, let’s take a brief look at ACADIA Pharmaceuticals Inc. (ACAD) price momentum. RSI 9-day as of the close on 13 October was 64.34%, suggesting the stock is Neutral, with historical volatility in this time frame at 36.76%.
As of today, ACAD’s price is $17.37 +5.75% or $0.97 from its 5-day moving average. ACAD is currently trading +12.20% higher than its 20-day SMA and -18.69% lower than its 100-day SMA. However, the stock’s current price level is -17.52% below the SMA50 and -66.45% below the SMA200.
The stochastic %K and %D were 70.62% and 56.51%, respectively, and the average true range (ATR) was 0.65. With the 14-day stochastic at 77.38% and the average true range at 0.66, the RSI (14) stands at 57.61%. The stock has reached 0.41 on the 9-day MACD Oscillator while the 14-day reading was at 0.47.
The consensus rating for ACADIA Pharmaceuticals Inc. (ACAD) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ACAD, while 14 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is ACAD’s price target for the next 12 months?
Analysts predict a range of price targets between $18.00 and $35.00, with a median target of $25.50. Taking a look at these predictions, the average price target given by analysts for ACADIA Pharmaceuticals Inc. (ACAD) stock is $25.50.